Ceftriaxone for Community-Acquired Pneumonia
For adults with moderate to severe community-acquired pneumonia without risk factors for Pseudomonas or MRSA, use ceftriaxone 1-2 g IV daily (or divided twice daily) combined with a macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily). Alternatively, a respiratory fluoroquinolone alone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) is equally effective 1, 2.
Recommended Regimens by Severity
Non-ICU Hospitalized Patients (Moderate Severity)
β-lactam plus macrolide combination therapy is strongly recommended 1:
- Ceftriaxone 1-2 g IV once daily PLUS azithromycin 500 mg daily OR clarithromycin 500 mg twice daily
- Alternative β-lactams: cefotaxime 1-2 g every 8 hours, ampicillin-sulbactam 1.5-3 g every 6 hours 2
- Doxycycline can substitute for the macrolide if needed 1
Alternative monotherapy:
- Respiratory fluoroquinolone alone: levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily 1
ICU Patients (Severe CAP)
Combination therapy is mandatory 1, 2:
- Ceftriaxone 1-2 g IV daily (or cefotaxime 1-2 g every 8 hours) PLUS either:
- Azithromycin 500 mg daily, OR
- Respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily)
Ceftriaxone Dosing: 1 g vs 2 g Daily
Ceftriaxone 1 g daily is as effective as 2 g daily for CAP in regions with low penicillin-resistant Streptococcus pneumoniae prevalence 3, 4, 5. A 2023 retrospective cohort of 3,989 patients found identical 30-day mortality between 1 g and 2 g daily (14.7% vs 16.0%, p=0.24), with 1 g showing lower C. difficile infection rates (0.2% vs 0.6%, p=0.03) and shorter hospital stays 3. Meta-analysis of 24 randomized trials confirmed no difference in clinical cure rates (OR 1.02,95% CI 0.91-1.14) 4.
Use 2 g daily when:
- Severe CAP requiring ICU admission
- Known or suspected drug-resistant S. pneumoniae in your region
- Meningitis concern (though not typical for CAP)
Use 1 g daily when:
- Non-severe CAP in general ward patients
- Low local resistance rates to penicillin/cephalosporins
- Concern for antibiotic-related adverse effects
The FDA label states "usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection" 6.
Why Combination Therapy Matters
Never use ceftriaxone monotherapy for CAP. The combination with a macrolide or fluoroquinolone is critical because:
- Ceftriaxone lacks activity against atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella species) which cause 10-40% of CAP cases 1
- Macrolides provide this atypical coverage and may have immunomodulatory benefits
- Combination therapy reduces mortality in severe CAP compared to β-lactam monotherapy 1
Duration of Therapy
Treat for minimum 5 days, continuing until clinically stable for 48-72 hours 1. Clinical stability means:
- Temperature ≤37.8°C
- Heart rate ≤100 beats/min
- Respiratory rate ≤24 breaths/min
- Systolic blood pressure ≥90 mmHg
- Oxygen saturation ≥90% on room air
- Able to take oral medications
Recent 2025 guidelines suggest shorter courses (3-5 days) may be adequate for non-severe CAP reaching clinical stability, though this represents evolving practice 7.
Administration Details
Administer ceftriaxone as IV infusion over 30 minutes 6. The FDA label specifies concentrations between 10-40 mg/mL are recommended.
Critical safety warning: Never mix ceftriaxone with calcium-containing solutions (Ringer's lactate, Hartmann's solution) due to precipitation risk. In neonates, this is absolutely contraindicated; in adults, flush lines thoroughly between infusions if sequential administration is necessary 6.
When to Modify This Approach
Add MRSA coverage (vancomycin 15 mg/kg IV every 8-12 hours OR linezolid 600 mg IV every 12 hours) if 2:
- Recent hospitalization with IV antibiotics in past 90 days
- Known MRSA colonization
- Severe necrotizing or cavitary pneumonia on imaging
- Post-influenza pneumonia
Add Pseudomonas coverage (switch to piperacillin-tazobactam 4.5 g every 6 hours, cefepime 2 g every 8 hours, or meropenem 1 g every 8 hours PLUS ciprofloxacin or levofloxacin) if 1, 2:
- Structural lung disease (bronchiectasis, cystic fibrosis)
- Recent hospitalization or antibiotics
- Severe immunosuppression
Common Pitfalls to Avoid
Don't use macrolide monotherapy in hospitalized patients—resistance rates of S. pneumoniae to macrolides exceed 20-30% in many regions 1, 8
Don't forget to add macrolide coverage when using ceftriaxone—this is the most common prescribing error 9
Don't continue antibiotics beyond clinical stability—prolonged courses increase adverse effects without improving outcomes 1
Don't use ceftriaxone if true penicillin allergy exists—use respiratory fluoroquinolone monotherapy instead 1
Don't assume higher doses are always better—1 g daily is sufficient for most non-severe CAP and reduces side effects 3, 4, 5
Switch to Oral Therapy
Transition to oral antibiotics when the patient meets clinical stability criteria (listed above) 1. Oral options include:
- Amoxicillin-clavulanate 875 mg twice daily PLUS azithromycin
- Levofloxacin 750 mg daily
- Moxifloxacin 400 mg daily
Patients can be discharged once stable on oral therapy—inpatient observation while receiving oral antibiotics is unnecessary 1.